Join us at ADLM 2025
Clinical Lab Expo

Elevating Impact: Transforming Lab Operations for Better Patient Care and a Greener Future

Tuesday, July 29th | 10:00am

Presentation Description:
See how strategic laboratory optimization delivered impactful results across one of Canada's largest Catholic healthcare networks -Unity Health Toronto. Facing complex challenges from turnaround time and specimen quality to sustainability, noise reduction, and physical space, they partnered with Beckman Coulter to deliver transformative change not just for their business, but for their patients and environment.

Speaker Bio:
Dr. Dan Beriault is Head of Clinical Biochemistry and Specimen Management at Unity Health Toronto, as well as an Associate Professor at University of Toronto. Dr. Beriault was the past chair of the CSCC laboratory utilization interest group and is currently the Provincial Chair of clinical biochemistry for Ontario Health. His academic interests span the fields of endocrinology, toxicology and appropriate laboratory utilization.

Stronger Together: Advancing Infectious Disease Diagnostics in Acute Care

Tuesday, July 29th | 11:00am

Presentation Description:
Laboratorians increasingly provide the critical diagnostic data that guides treatment decisions and precision medicine. Finding the right diagnostic solution partner can further elevate laboratory leadership through clinical, technological, and operational innovation. This session explores how the cross-disciplinary implementation of novel biomarkers, high resolution instruments, and AI-driven clinical decision support empowers lab teams to better partner with providers managing complex acute infectious disease.

Speaker Bios:
Dr. Cristina Baker, Senior Director Medical Affairs, Cepheid
Dr. Stephanie Mitchell, Senior Director, Scientific Affairs, Beckman Coulter Microbiology
Dr. Kasper Andersen , Senior Medical Advisor, Radiometer
Dr. Melissa Naiman, Medical Director, Beckman Coulter

Bottoms Up: Tackling Clostridioides difficile and Gram-Negative Resistance at the Source

Tuesday, July 29th | 12:00pm

Presentation Description:
This presentation will highlight the utility of stool andrectal swab testing to directly detect Clostridioides difficile and antimicrobial resistance gene targets in Gram-negative bacilli. This approach enables real-time epidemiologic surveillance for critical HAI pathogens and supports targeted treatment decisions based on the antimicrobial resistance mechanisms identified.

Speaker Bio:
Nicholas Moore, Ph.D., D(ABMM), MLS(ASCP)CM, is an associate professor at Rush University and is the associate director of the Division of Clinical Microbiology, Department of Pathology, and director of the Biocontainment Laboratory at Rush University Medical Center. Dr. Moore is board-certified in medical and public health microbiology. His research focuses on the epidemiology of multiple drug-resistant organisms, antiseptic and biocide resistance in Gram-negative bacilli, and the use of advanced molecular diagnostics to inform infection control decision-making related to nosocomial outbreaks. Dr. Moore is president of the Illinois Society of Microbiology, a volunteer with ASM and CLSI, and a member of the College of American Pathologists Microbiology Committee.

The Crucial First Steps: Preanalytical Factors in Blood Gas Testing

Tuesday, July 29th | 1:00pm

Presentation Description:
Coming soon.

Speaker Bio:
Julie Shaw is Head of the Division of Biochemistry and Director of POCT at the Eastern Ontario Regional Laboratories Association in Ottawa, Canada. She is an Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Ottawa. Julie chairs the POCT Special Interest Group for the Canadian Society of Clinical Chemists, is chair elect of the ADLM POCT Division and is a member of the IFCC POCT working group. Her research interests are related to quality assurance practices for POCT both in the hospital and in community settings.

Maximizing Efficiency in the Hematology Laboratory Operations

Tuesday, July 29th | 2:00pm

Presentation Description:
Discover how Dr. Olga Pozdnyakova leverages DxH technology to significantly boost staff productivity and minimize manual review rates in the hematology laboratory at Penn Medicine. Through innovative applications of this cutting-edge technology, Dr. Pozdnyakova is streamlining laboratory processes, enhancing efficiency, and ensuring high-quality diagnostic outcomes.

Speaker Bio:

Dr. Olga Pozdnyakova is a distinguished specialist in hematopathology, with extensive clinical expertise in laboratory hematology, flow cytometry, and the diagnostic approach to hematologic disorders, including leukemias, lymphomas, myelomas, and mast cell disorders. After receiving an MD in Internal Medicine from Russian State Medical University and a PhD in Pediatric Hematology from the Federal Clinical Research Center in Moscow, Dr. Pozdnyakova pursued extensive postgraduate training, including residencies and fellowships at prestigious institutions such as Harvard Medical School and Brigham and Women’s Hospital. Board-certified in Anatomic and Clinical Pathology and Hematopathology by the American Board of Pathology, Dr. Pozdnyakova has made significant contributions to research, focusing on developing new testing algorithms for hematologic neoplasms and discovering novel characteristics of hematopoietic cells for diagnostic and predictive modeling. Dr. Pozdnyakova has been recognized with numerous awards, including the Excellence in Urologic Pathology Research Award and the Partners in Excellence Award, and has been an integral part of the COVID-19 response team at Brigham & Women’s Hospital. With leadership roles in several professional organizations, including the United States and Canadian Academy of Pathology, the American Society for Clinical Pathology, and the College of American Pathologists, Dr. Pozdnyakova continues to contribute to advancing the field through education and research. She is committed to excellence in both clinical practice and academic leadership, demonstrated by a history of directing educational courses and involvement in key committees across multiple prestigious societies.

Slide into the Future – Unlocking the Potential of AI

Tuesday, July 29th | 3:00pm

Presentation Description:
This presentation explores the transformative role of artificial intelligence in pathology, highlighting emerging market trends, workflow innovations, and AI-driven advancements. It culminates in a compelling call to action—urging adoption to accelerate digital diagnostics, improve patient outcomes, and advance healthcare equity.

Speaker Bio:

Mark Frushone is the Global Director of Commercial Development Digital Pathology at Leica Biosystems, based in Vista, California. With over 25 years of experience in the Health Care industry, Mark has been a prominent leader in the field. He joined Leica Biosystems in 2012 as a Market Manager for Emerging Markets, where he focused on digital pathology enablement across the globe. Prior to this role, Mark served as a Senior Application Specialist for the In-Direct Channel at Aperio Inc. Mark has been involved in the laboratory and digital pathology space for over 15 years. He holds a Master's degree in Education from National University and a Bachelor of Science from Central Connecticut.

Emerging and Evolving Respiratory Viruses: Test Design Matters!

Tuesday, July 29th | 4:00pm

Presentation Description:
Respiratory viruses, including influenza viruses, RSV and SARS-CoV-2 (the virus that causes COVID-19)continue to cause significant morbidity, mortality, and economic burden. Accurate and quick diagnosis in the laboratory or at the point of care is important to effectively manage infections, drive appropriate use of antiviral treatment, and reduce disease transmission. These viruses change over time, driving the emergence of new strains and variants that can challenge the performance of diagnostic tests. It is crucial that these tests are designed with the robustness to detect newly emerging strains of respiratory viruses.

Speaker Bio:

Mike Loeffelholz

From Core Lab to Community: Optimizing HIV Testing

Wednesday, July 30th | 10:00am

Presentation Description:
Discover how Marshfield Clinic Health System is optimizing HIV diagnostic services by standardizing testing across its extensive network. In this session, Dr. Sarah W. Bissonnette will present how the core laboratory has enhanced assay precision—enabling earlier detection and staging of HIV, while also improving turnaround time. Gain insights into how centralized operations and an expanded test menu are broadening access to high-quality diagnostics for the community and supporting future system-wide consolidation.

Speaker Bio:
Dr. Sarah W. Bissonnette is a board-certified clinical chemist at Marshfield Clinic Health System-Sanford Health in Marshfield, WI, where she serves as a Laboratory Director, Section Head, Program Director, and Consultant. Dr. Bissonnette also serves as a faculty member in the MLS training program at Marshfield Medical Center. She completed both her PhD in Pathology, Microbiology and Immunology and her Clinical Chemistry fellowship at Vanderbilt University Medical Center. Dr. Bissonnette is a Diplomate of the American Board of Clinical Chemistry and an active member of the Association for Diagnostics and Laboratory Medicine and the Academy of Clinical Laboratory Physicians and Scientists. As a laboratory director at Marshfield Clinic Health System, Dr. Bissonnette plays an instrumental role in advancing laboratory medicine. Her work is driven by a commitment to clinical diagnostic innovation and interdisciplinary collaboration, with a deep passion for improving patient care.

Driving Quality and Efficiency in Acute Care Testing Through Informatics

Wednesday, July 30th | 11:00am

Presentation Description:
Coming soon.

Speaker Bio:
Dr. Jessica M. Colón-Franco is the Medical Director of the Special Chemistry Laboratory and the Blood Gas Laboratory at Cleveland Clinic, as well as adjunct faculty at Cleveland State University in Cleveland, OH. Dr. Colón-Franco provided strategic, clinical, and scientific direction to the laboratories within her section, driving advancements in clinical chemistry and enhancing patient care when she served as Section Head of Clinical Biochemistry. She completed her fellowship training in Clinical Chemistry at Vanderbilt University Medical Center in Nashville, TN.
Dr. Colón-Franco is a diplomate of the American Board of Clinical Chemistry, a fellow of the ADLM Academy, and an active member of several laboratory medicine associations. She has held various committee roles, including member and current chair of the Latin American Working Group of ADLM's Global Affairs program and chair-elect of the Health Equity & Access Division. Dr. Colón-Franco’s professional interests center on acute care testing, endocrinology, therapeutic drug monitoring and toxicology, mass spectrometry, neurological and inflammatory biomarkers. Her work continues to focus on improving laboratory practices and advancing clinical chemistry through clinical service, research, and education.

Unlocking Operational Excellence: LCMC Transformative Partnership with Beckman Coulter

Wednesday, July 30th | 12:00pm

Presentation Description:
Coming soon.

Speaker Bio:
Tracy Moll

Innovating Patient Care: Blood-based Biomarkers for Neurodegenerative Diseases

Wednesday, July 30th | 1:00pm

Presentation Description:
This session will address the growing global impact of Alzheimer’s disease, highlighting its epidemiology and unmet clinical needs. It will explore the disease’s pathophysiology and the role of current and emerging blood-based biomarkers in diagnosis and monitoring, with attention to assay performance. The presentation will also examine the future of biomarker development and their integration into clinical practice.

Speaker Bio:

Jean-Sébastien Blanchet is a PhD-trained immunologist with a career focused on advancing diagnostic innovation to improve patient care. After early work in DNA vaccine development at GSK, Jean-Sebastien joined Beckman Coulter, where he’s led scientific, clinical, and health economic initiatives across Europe and globally. Currently serving as the Director of Global Medical and Scientific Affairs, he’s driving evidence generation for diagnostics in neurodegenerative and infectious diseases. Jean-Sébastien serves as Beckman Coulter’s representative to international bodies including the IFCC.

The Health Economic Value of Using Monocyte Distribution Width (MDW) in Patients Presenting with Sepsis in an U.S. Emergency Department

Wednesday, July 30th | 2:00pm

Presentation Description:
MDW is a hematology parameter developed by Beckman Coulter that can help identify patients with sepsis or those at an increased risk of developing sepsis within the first 12 hours of hospital admission. In this study, we present the health economic impact of implementing MDW testing for early sepsis detection in the emergency department, using real-world data from a U.S. emergency department.

Speaker Bio:

Lopamudra Das is the Director of Health Economics and Outcomes Research at Beckman Coulter. With ten years of experience in consulting and diagnostics, she has successfully led numerous Health Economics and Outcomes Research (HEOR) projects across various therapeutic areas. Lopamudra holds a PhD from the RAND Graduate School and a Master’s in Public Health from San Diego State University.

Slide into the Future – Unlocking the Potential of AI

Wednesday, July 30th | 3:00pm

Presentation Description:
This presentation explores the transformative role of artificial intelligence in pathology, highlighting emerging market trends, workflow innovations, and AI-driven advancements. It culminates in a compelling call to action—urging adoption to accelerate digital diagnostics, improve patient outcomes, and advance healthcare equity.

Speaker Bio:

Mark Frushone is the Global Director of Commercial Development Digital Pathology at Leica Biosystems, based in Vista, California. With over 25 years of experience in the Health Care industry, Mark has been a prominent leader in the field. He joined Leica Biosystems in 2012 as a Market Manager for Emerging Markets, where he focused on digital pathology enablement across the globe. Prior to this role, Mark served as a Senior Application Specialist for the In-Direct Channel at Aperio Inc. Mark has been involved in the laboratory and digital pathology space for over 15 years. He holds a Master's degree in Education from National University and a Bachelor of Science from Central Connecticut.